Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
2183440-63-1 | Cy7 hydrazide | AA019EGI | MFCD31580092
925886-35-7 | 4-Nitro-N-(3-oxo-3-(pyrrolidin-1-yl)propyl)benzenesulfonamide | AA019EJN | MFCD09432956
1321901-45-4 | 4-aminocarbonyl-2-thienylBoronic acid pinacol ester | AA019EMQ | MFCD31652768
535935-39-8 | (E)-Chroman-4-one oxime | AA019EPX | MFCD00463254
103904-94-5 | (3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one | AA019ET0 | MFCD14279172
1000705-54-3 | 4-(3-bromophenyl)oxane-4-carbonitrile | AA019EW9 | MFCD10690833
168132-18-1 | 3-(3-methoxy-4-methylphenyl)propan-1-ol | AA019EZ8 | MFCD09999377
871254-63-6 | 6-Chloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine | AA019FUT | MFCD09802041
326610-63-3 | 2-hydroxy-4-(3-nitrobenzenesulfonamido)benzoic acid | AA019GFO | MFCD02699971
519152-08-0 | 4-[(2-methoxy-5-nitrophenyl)sulfamoyl]benzoic acid | AA019GL2 | MFCD03480003